

Enriqueta Felip

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6041998/publications.pdf>

Version: 2024-02-01

260
papers

67,869
citations

5126

86
h-index

850

251
g-index

265
all docs

265
docs citations

265
times ranked

40917
citing authors

#	ARTICLE	IF	CITATIONS
1	Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 241-251.	13.9	393
2	Future care for long-term cancer survivors: towards a new model. <i>Clinical and Translational Oncology</i> , 2022, 24, 350-362.	1.2	2
3	Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study. <i>Lung Cancer</i> , 2022, 163, 7-13.	0.9	6
4	SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021). <i>Clinical and Translational Oncology</i> , 2022, 24, 635-645.	1.2	6
5	Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). <i>Lung Cancer</i> , 2022, 166, 107-113.	0.9	3
6	ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. <i>Annals of Oncology</i> , 2022, 33, 466-487.	0.6	67
7	MARIPOSA: phase 3 study of first-line amivantamab plus azertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 639-647.	1.1	44
8	Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data. <i>Annals of Oncology</i> , 2022, 33, 511-521.	0.6	36
9	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 499-514.	1.1	7
10	Encorafenib plus binimetinib in patients with <i>BRAF</i> ^{V600} -mutant non-small cell lung cancer: phase II PHAROS study design. <i>Future Oncology</i> , 2022, 18, 781-791.	1.1	9
11	Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report. <i>Frontiers in Oncology</i> , 2022, 12, 837630.	1.3	0
12	SEOM clinical guidelines (2021). <i>Clinical and Translational Oncology</i> , 2022, 24, 611-612.	1.2	0
13	Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 166, 170-177.	0.9	4
14	Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1973-1985.	13.9	871
15	High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC. <i>Lung Cancer</i> , 2022, 10, e004197.		5
16	Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). <i>Journal of Thoracic Oncology</i> , 2021, 16, 278-288.	0.5	82
17	Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Molecular Oncology</i> , 2021, 15, 887-900.	2.1	24
18	Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 93-102.	1.5	31

#	ARTICLE	IF	CITATIONS
19	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 198-211.	5.1	773
20	Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors. <i>Nephrology Dialysis Transplantation</i> , 2021, , .	0.4	23
21	Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 723-733.	0.8	329
22	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. <i>Radiology</i> , 2021, 299, 109-119.	3.6	54
23	Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM). <i>ESMO Open</i> , 2021, 6, 100048.	2.0	7
24	Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. <i>Annals of Oncology</i> , 2021, 32, 620-630.	0.6	60
25	Interrelations between Patientsâ€™™ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients. <i>Cancers</i> , 2021, 13, 3249.	1.7	9
26	Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey. <i>ESMO Open</i> , 2021, 6, 100131.	2.0	19
27	Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naïve Programmed Death-Ligand 1â€“Selected NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1872-1882.	0.5	85
28	Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. <i>Annals of Oncology</i> , 2021, 32, 881-895.	0.6	213
29	LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. <i>Cancer Medicine</i> , 2021, 10, 5878-5888.	1.3	11
30	Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 157, 9-16.	0.9	7
31	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. <i>EClinicalMedicine</i> , 2021, 37, 100940.	3.2	11
32	Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2021, 32, 1597-1607.	0.6	47
33	Brigatinib Versus Crizotinib in ALK Inhibitorâ€“Naïve Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2091-2108.	0.5	156
34	Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. <i>European Journal of Cancer</i> , 2021, 155, 168-178.	1.3	1
35	Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IBâ€“IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet</i> , The, 2021, 398, 1344-1357.	6.3	689
36	Female leadership in oncologyâ€“has progress stalled? Data from the ESMO W4O authorship and monitoring studies. <i>ESMO Open</i> , 2021, 6, 100281.	2.0	9

#	ARTICLE	IF	CITATIONS
37	First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. <i>ESMO Open</i> , 2021, 6, 100273.	2.0	91
38	Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, e214761.	3.4	160
39	Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. <i>Clinical and Translational Oncology</i> , 2020, 22, 759-771.	1.2	11
40	Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2020, 22, 989-1003.	1.2	59
41	Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study. <i>Journal of Thoracic Oncology</i> , 2020, 15, 392-403.	0.5	51
42	Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients. <i>Clinical and Translational Oncology</i> , 2020, 22, 1390-1398.	1.2	12
43	Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 416-425.	0.5	17
44	Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria. <i>Clinical Cancer Research</i> , 2020, 26, 1846-1855.	3.2	70
45	Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 609-617.	0.5	27
46	First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2018-2029.	13.9	592
47	Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study. <i>BMC Psychology</i> , 2020, 8, 123.	0.9	0
48	Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3592-3603.	0.8	224
49	Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 944-957.	13.9	542
50	Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT). <i>Journal of Clinical Oncology</i> , 2020, 38, 1132-1143.	3.2	169
51	Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. <i>New England Journal of Medicine</i> , 2020, 383, 931-943.	13.9	500
52	Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours. <i>Nature Communications</i> , 2020, 11, 3157.	5.8	59
53	Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) – A decision-making analysis amongst European lung cancer experts. <i>Lung Cancer</i> , 2020, 146, 6-11.	0.9	8
54	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1505-1517.	0.8	710

#	ARTICLE	IF	CITATIONS
55	Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 144, 10-19.	0.9	14
56	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β 2 and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1210-1222.	0.5	119
57	Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 387-397.	5.1	119
58	Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer. <i>Targeted Oncology</i> , 2020, 15, 55-65.	1.7	86
59	Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 561-572.	5.2	47
60	Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. <i>Radiotherapy and Oncology</i> , 2020, 149, 84-88.	0.3	13
61	The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1434-1448.	0.5	107
62	Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. <i>New England Journal of Medicine</i> , 2020, 383, 1328-1339.	13.9	959
63	Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. <i>Lung Cancer</i> , 2019, 135, 188-195.	0.9	189
64	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1655-1669.	5.1	418
65	An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 136, 74-79.	0.9	14
66	Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2120-2132.	0.5	48
67	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 133, 163-166.	0.3	24
68	Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. <i>Lung Cancer</i> , 2019, 134, 72-78.	0.9	24
69	Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2518-2527.	0.8	811
70	Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1266-1276.	0.5	78
71	Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1086-1094.	0.5	99
72	Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 793-801.	0.5	50

#	ARTICLE	IF	CITATIONS
73	Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancerâ€”The ETOP NICOLAS trial. Lung Cancer, 2019, 133, 83-87.	0.9	113
74	Clinical Management of Adverse Events Associated with Lorlatinib. Oncologist, 2019, 24, 1103-1110.	1.9	101
75	Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiotherapy and Oncology, 2019, 135, 74-77.	0.3	14
76	Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Lancet Respiratory Medicine, the, 2019, 7, 347-357.	5.2	137
77	Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. JCO Precision Oncology, 2019, 3, 1-14.	1.5	17
78	<i>ALK</i> Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Nonâ€”Small-Cell Lung Cancer. Journal of Clinical Oncology, 2019, 37, 1370-1379.	0.8	282
79	Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Cancer Immunology, Immunotherapy, 2019, 68, 341-352.	2.0	82
80	Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. Oncologist, 2019, 24, 1095-1102.	1.9	37
81	A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. ESMO Open, 2019, 4, e000532.	2.0	13
82	Epidermal growth factor receptor first generation tyrosine-kinase inhibitors. Translational Lung Cancer Research, 2019, 8, S235-S246.	1.3	8
83	5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging. Thorax, 2019, 74, 371-379.	2.7	9
84	Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. Clinical Lung Cancer, 2019, 20, e407-e412.	1.1	12
85	Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. European Journal of Cancer, 2019, 108, 120-128.	1.3	50
86	Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. Annals of Oncology, 2019, 30, 281-289.	0.6	88
87	Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Annals of Oncology, 2019, 30, 161-165.	0.6	60
88	Lung cancer in Spanish women: The WORLD07 project. European Journal of Cancer Care, 2019, 28, e12941.	0.7	6
89	KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.. Journal of Clinical Oncology, 2019, 37, 9013-9013.	0.8	42
90	Pembrolizumab plus Chemotherapy in Metastatic Nonâ€”Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 2078-2092.	13.9	4,701

#	ARTICLE	IF	CITATIONS
91	Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate) Tj ETQq1 1 0.784314 rgBT /Overlo Oncology, 2018, 29, 959-965.	0.6	388
92	Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Annals of Oncology, 2018, 29, i20-i27.	0.6	159
93	Second-Line Treatment Options in Non-“Small-Cell” Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 2018, 19, 301-314.	1.1	7
94	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. Journal of Thoracic Oncology, 2018, 13, 413-425.	0.5	66
95	Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 576-584.	0.5	62
96	Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-“Small Cell Lung Cancer. JAMA Oncology, 2018, 4, 351.	3.4	599
97	CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Annals of Oncology, 2018, 29, 687-693.	0.6	193
98	Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project. Annals of Oncology, 2018, 29, 200-208.	0.6	25
99	Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. Clinical Lung Cancer, 2018, 19, 74-83.e11.	1.1	28
100	Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With <i>EGFR</i>-Mutated, MET Factor-“Dysregulated Non-“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 3101-3109.	0.8	252
101	Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2251-2258.	0.8	308
102	OA12.01 Phase II Data for the MET Inhibitor Tepotinib in Patients with Advanced NSCLC and MET Exon 14-Skipping Mutations. Journal of Thoracic Oncology, 2018, 13, S347.	0.5	15
103	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1818-1831.	0.5	133
104	Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncology, The, 2018, 19, 1654-1667.	5.1	587
105	Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nature Communications, 2018, 9, 4655.	5.8	107
106	Brigatinib versus Crizotinib in <i>ALK</i>-Positive Non-“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 379, 2027-2039.	13.9	691
107	HIV-Positive Patients with Lung Cancer: Is Immunotherapy a Safe and Active Option for Them?. Journal of Thoracic Oncology, 2018, 13, 874-876.	0.5	5
108	Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. European Journal of Cancer, 2018, 101, 201-209.	1.3	41

#	ARTICLE	IF	CITATIONS
109	Association of <i>ERBB</i> Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1189.	3.4	53
110	Health-related quality of life (HRQoL) in the KEYNOTE-189 study of pembrolizumab (pembro) or placebo (pbo) + pemetrexed (pem) + platinum (plt) for metastatic NSCLC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9021-9021.	0.8	15
111	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. <i>Journal of Clinical Oncology</i> , 2017, 35, 1288-1296.	0.8	470
112	Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches. <i>Lung Cancer</i> , 2017, 106, 70-75.	0.9	30
113	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 435-444.	5.2	172
114	Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. <i>Annals of Oncology</i> , 2017, 28, 874-881.	0.6	197
115	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. <i>Cancer Research</i> , 2017, 77, 3540-3550.	0.4	327
116	First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 2415-2426.	13.9	2,145
117	Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 874-886.	5.1	453
118	Evaluation of the VeriStrat [®] serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. <i>Lung Cancer</i> , 2017, 109, 101-108.	0.9	25
119	Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. <i>Clinical Cancer Research</i> , 2017, 23, 5406-5415.	3.2	29
120	The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. <i>Cancer Treatment Reviews</i> , 2017, 55, 181-189.	3.4	12
121	OA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1-Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study. <i>Journal of Thoracic Oncology</i> , 2017, 12, S251-S252.	0.5	13
122	OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057. <i>Journal of Thoracic Oncology</i> , 2017, 12, S253.	0.5	46
123	Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07. <i>Cancer Investigation</i> , 2017, 35, 358-365.	0.6	9
124	Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists. <i>Clinical and Translational Oncology</i> , 2017, 19, 508-518.	1.2	13
125	Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. <i>Lancet Oncology</i> , 2017, 18, 1590-1599.	5.1	535
126	A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer. <i>Annals of Oncology</i> , 2017, 28, 2241-2247.	0.6	15

#	ARTICLE	IF	CITATIONS
127	DualMET andERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2017, 28, 2451-2457.	0.6	58
128	Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database. <i>Clinical and Translational Oncology</i> , 2017, 19, 1537-1542.	1.2	4
129	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, 194-207.	0.5	186
130	A consensus statement on the gender perspective in lung cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 527-535.	1.2	26
131	Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. <i>Nature Communications</i> , 2017, 8, 410.	5.8	117
132	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017, 35, 2781-2789.	0.8	348
133	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and Tj ETQq1 1 0784314 rgt /Over	0.8	314
134	Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?. <i>Translational Lung Cancer Research</i> , 2017, 6, S78-S83.	1.3	9
135	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017, 35, 2781-2789.	0.8	24
136	Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 2502-2502.	0.8	27
137	Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9006-9006.	0.8	20
138	KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9011-9011.	0.8	18
139	Factors associated with better overall survival (OS) in patients with previously treated, PD-L1-expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9090-9090.	0.8	14
140	NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)-positive NSCLC. <i>Annals of Oncology</i> , 2016, 27, vi577.	0.6	66
141	A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2016, 27, vi452.	0.6	2
142	Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. <i>Journal of Clinical Oncology</i> , 2016, 34, 2858-2865.	0.8	216
143	Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). <i>Lung Cancer</i> , 2016, 96, 1-6.	0.9	31
144	Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2016, 27, 1291-1298.	0.6	129

#	ARTICLE	IF	CITATIONS
145	Thoracic oncology HERMES: European curriculum recommendations for training in thoracic oncology. <i>Breathe</i> , 2016, 12, 249-255.	0.6	18
146	P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab. <i>Journal of Thoracic Oncology</i> , 2016, 11, S241-S242.	0.5	18
147	Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1479-1489.	1.4	10
148	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3740-3748.	0.8	438
149	A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS). <i>Lung Cancer</i> , 2016, 99, 94-101.	0.9	11
150	Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With <i>ALK</i> -Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 2866-2873.	0.8	316
151	Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC. <i>Annals of Oncology</i> , 2016, 27, vi422.	0.6	6
152	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. <i>Lancet</i> , 2016, 387, 1540-1550.	6.3	5,456
153	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , 2016, 27, 417-423.	0.6	122
154	Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 801-807.	0.5	21
155	Activity and safety of ceritinib in patients with <i>ALK</i> -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. <i>Lancet Oncology</i> , 2016, 17, 452-463.	5.1	418
156	The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2016, 17, 161-168.	1.1	13
157	Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 767-776.	1.1	118
158	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. <i>Lancet Oncology</i> , 2016, 17, 212-223.	5.1	158
159	Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010. <i>Journal of Clinical Oncology</i> , 2016, 34, 9024-9024.	0.8	7
160	Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses. <i>Journal of Clinical Oncology</i> , 2016, 34, 9025-9025.	0.8	26
161	Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro). <i>Journal of Clinical Oncology</i> , 2016, 34, 9026-9026.	0.8	31
162	Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M. <i>Journal of Clinical Oncology</i> , 2016, 34, 9044-9044.	0.8	28

#	ARTICLE	IF	CITATIONS
163	Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07. <i>Anticancer Research</i> , 2016, 36, 6647-6654.	0.5	9
164	BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. <i>Scientific Reports</i> , 2015, 5, 17499.	1.6	55
165	El c�ncer de pulm�n en mujeres. <i>Arbor</i> , 2015, 191, a235.	0.1	0
166	Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus. <i>Lung Cancer</i> , 2015, 87, 89-95.	0.9	40
167	Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2015, 17, 103-112.	1.2	23
168	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 897-907.	5.1	389
169	AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1689-1699.	13.9	1,802
170	Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2015, 16, 325-333.	1.1	65
171	Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 2018-2028.	13.9	5,183
172	Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. <i>JAMA Oncology</i> , 2015, 1, 149.	3.4	224
173	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 1573-1588.	0.6	308
174	Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. <i>Nature Medicine</i> , 2015, 21, 560-562.	15.2	1,280
175	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1627-1639.	13.9	7,973
176	A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). <i>Annals of Oncology</i> , 2015, 26, 1741-1748.	0.6	87
177	ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8059-8059.	0.8	43
178	ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALK-na�ve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8060-8060.	0.8	51
179	Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA109-LBA109.	0.8	74
180	Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM). <i>PLoS ONE</i> , 2015, 10, e0121071.	1.1	185

#	ARTICLE	IF	CITATIONS
181	Efficacy and Safety of Ceritinib in Patients (Pts) with Advanced Anaplastic Lymphoma Kinase (Alk)-Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc): an Update of Ascend-1. Annals of Oncology, 2014, 25, iv456.	0.6	24
182	Overall and Intracranial (Ic) Efficacy Results and Time to Symptom Deterioration in Profile 1014: 1St-Line Crizotinib Vs Pemetrexed - Platinum Chemotherapy (Ppc) in Patients (Pts) with Advanced Alk-Positive Non-Squamous Non-Small Cell Lung Cancer (Nsclc). Annals of Oncology, 2014, 25, iv427.	0.6	9
183	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Annals of Oncology, 2014, 25, 1475-1484.	0.6	210
184	First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer. New England Journal of Medicine, 2014, 371, 2167-2177.	13.9	2,808
185	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology, 2014, 25, 1681-1690.	0.6	246
186	Lungscape: Resected Nonâ€™Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters. Journal of Thoracic Oncology, 2014, 9, 1675-1684.	0.5	31
187	Unusual forms of subacute invasive pulmonary aspergillosis in patients with solid tumors. Journal of Infection, 2014, 69, 387-395.	1.7	16
188	Lung cancer in women: an overview with special focus on Spanish women. Clinical and Translational Oncology, 2014, 16, 517-528.	1.2	22
189	Ceritinib in <i>ALK</i>-Rearranged Nonâ€™Small-Cell Lung Cancer. New England Journal of Medicine, 2014, 370, 1189-1197.	13.9	1,367
190	2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, 1462-1474.	0.6	410
191	The Impact of <i>EGFR</i> T790M Mutations and <i>BIM</i> mRNA Expression on Outcome in Patients with <i>EGFR</i>-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial. Clinical Cancer Research, 2014, 20, 2001-2010.	3.2	215
192	Molecular targeted therapy for early-stage non-small-cell lung cancer: Will it increase the cure rate?. Lung Cancer, 2014, 84, 97-100.	0.9	19
193	Evaluation of Ceritinib-Treated Patients (Pts) with Anaplastic Lymphoma Kinase Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc) and Brain Metastases in the Ascend-1 Study. Annals of Oncology, 2014, 25, iv455.	0.6	17
194	First-line crizotinib versus pemetrexedâ€™cisplatin or pemetrexedâ€™carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). Journal of Clinical Oncology, 2014, 32, 8002-8002.	0.8	44
195	Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.. Journal of Clinical Oncology, 2014, 32, 8003-8003.	0.8	24
196	A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.. Journal of Clinical Oncology, 2014, 32, 8051-8051.	0.8	22
197	SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013. Clinical and Translational Oncology, 2013, 15, 977-984.	1.2	18
198	Strategies for improving outcomes in NSCLC: A look to the future. Lung Cancer, 2013, 82, 375-382.	0.9	29

#	ARTICLE	IF	CITATIONS
199	An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1529-1537.	0.5	33
200	Thoracic Oncology HERMES: a European syllabus towards a harmonised education and training of Thoracic Oncology specialists. <i>Breathe</i> , 2013, 9, 381-392.	0.6	5
201	Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic Perspectives. <i>Journal of Clinical Oncology</i> , 2013, 31, 1997-2003.	0.8	572
202	Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013, 24, vi99-vi105.	0.6	490
203	Thoracic Oncology HERMES syllabus: setting the basis for thoracic oncology training in Europe: Table 1. <i>European Respiratory Journal</i> , 2013, 42, 568-571.	3.1	23
204	Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel <i>HER2</i> V659E Mutation. <i>Cancer Discovery</i> , 2013, 3, 1238-1244.	7.7	43
205	Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013, 24, vi89-vi98.	0.6	440
206	Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e52261.	1.1	68
207	<i>HER2</i> driven non-small cell lung cancer (NSCLC): potential therapeutic approaches. <i>Translational Lung Cancer Research</i> , 2013, 2, 122-7.	1.3	43
208	Neoadjuvant chemotherapy in early-stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2013, 2, 398-402.	1.3	10
209	Adjuvant Chemotherapy: Feasibility in the Elderly and Patient Selection. , 2013, , 165-172.		0
210	Is There a Role for Neoadjuvant Chemotherapy in Older Patients?. , 2013, , 141-150.		0
211	DNA repair protein expression in resected NSCLC: a different predictive value for platinum benefit in adenocarcinoma versus squamous-cell carcinoma?. <i>Annals of Oncology</i> , 2012, 23, 2211-2214.	0.6	4
212	Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012, 23, vii56-vii64.	0.6	647
213	Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung trial (MO19390). <i>Journal of Thoracic Oncology</i> , 2012, 7, 203-211.	0.5	70
214	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 239-246.	5.1	4,943
215	Recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón no microcítico avanzado. Consenso nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica. <i>Revista Española De Patología</i> , 2012, 45, 14-28.	0.6	9
216	Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). <i>Lung Cancer</i> , 2012, 77, 192-198.	0.9	64

#	ARTICLE	IF	CITATIONS
217	Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. <i>Molecular Oncology</i> , 2012, 6, 15-26.	2.1	66
218	Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). <i>Clinical and Translational Oncology</i> , 2012, 14, 338-349.	1.2	35
219	Never-smoking women with lung cancer from the Spanish WORLD07 database.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1531-1531.	0.8	1
220	Population survey to assess the knowledge of smoking habit and its consequences on women (w) in Spain.. <i>Journal of Clinical Oncology</i> , 2012, 30, e12000-e12000.	0.8	1
221	Menstrual status and lung cancer in female patients from the Spanish WORLD07 database.. <i>Journal of Clinical Oncology</i> , 2012, 30, e12012-e12012.	0.8	3
222	Adjuvant and neoadjuvant therapy of non-small cell lung cancer. , 2012, , 93-103.		0
223	Tissue sampling in lung cancer: A review in light of the MERIT experience. <i>Lung Cancer</i> , 2011, 74, 1-6.	0.9	40
224	Adjuvant Therapy in Non-Small Cell Lung Cancer: Future Treatment Prospects and Paradigms. <i>Clinical Lung Cancer</i> , 2011, 12, 261-271.	1.1	32
225	1st ESMO Consensus Conference in lung cancer; Lugano 2010: Small-cell lung cancer. <i>Annals of Oncology</i> , 2011, 22, 1973-1980.	0.6	56
226	Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy. <i>Annals of Oncology</i> , 2011, 22, 1507-1519.	0.6	117
227	Expression of ErbB2 and ErbB3 in resected non-small cell lung cancer (NSCLC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2011, 29, 7037-7037.	0.8	1
228	Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.. <i>Journal of Clinical Oncology</i> , 2011, 29, 7503-7503.	0.8	97
229	SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition. <i>Clinical and Translational Oncology</i> , 2010, 12, 735-741.	1.2	13
230	Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v120-v125.	0.6	81
231	Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3138-3145.	0.8	351
232	A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2010, 21, 217-222.	0.6	40
233	How to integrate current knowledge in selecting patients for first line in NSCLC?. <i>Annals of Oncology</i> , 2010, 21, vii230-vii233.	0.6	5
234	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v116-v119.	0.6	273

#	ARTICLE	IF	CITATIONS
235	Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v103-v115.	0.6	456
236	Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3131-3137.	0.8	136
237	Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study. <i>Lung Cancer</i> , 2010, 70, 180-187.	0.9	41
238	A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, 3015-3015.	0.8	21
239	Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009, 20, iv68-iv70.	0.6	136
240	SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). <i>Clinical and Translational Oncology</i> , 2009, 11, 284-289.	1.2	14
241	Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second- and third line erlotinib. <i>Lung Cancer</i> , 2009, 66, 257-261.	0.9	16
242	Lung cancer in women: The Spanish female-specific database WORLD 07. <i>Journal of Clinical Oncology</i> , 2009, 27, 8084-8084.	0.8	1
243	Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. <i>Journal of Clinical Oncology</i> , 2009, 27, 8098-8098.	0.8	16
244	Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bac2/BCG in responding patients with limited disease small-cell lung cancer. <i>European Journal of Cancer</i> , 2008, 44, 2178-2184.	1.3	39
245	Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008, 19, ii39-ii40.	0.6	61
246	A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2008, 14, 3867-3874.	3.2	73
247	A phase II study of first-line erlotinib in patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC) including dose escalation to toxicity in current and former smokers (C/FS). <i>Journal of Clinical Oncology</i> , 2008, 26, 8111-8111.	0.8	3
248	Adjuvant chemotherapy in non-small cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2007, 18, ix143-ix146.	0.6	3
249	Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2747-2754.	0.8	445
250	Sex differences in non-small cell lung cancer (NSCLC) patients (p) participating in Spanish Lung Cancer Group (SLCG) trials. <i>Journal of Clinical Oncology</i> , 2007, 25, 7679-7679.	0.8	1
251	The expanding role of systemic treatment in non-small cell lung cancer neo-adjuvant therapy. <i>Annals of Oncology</i> , 2006, 17, x108-x112.	0.6	2
252	Phase III Study of Adjuvant Vaccination With Bac2/Bacille Calmette-Guerin in Responding Patients With Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and Treatment of Cancer) Tj ETQq0 00.8gBT/Ovarlock 10	0.8	1

#	ARTICLE	IF	CITATIONS
253	BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. <i>Human Molecular Genetics</i> , 2004, 13, 2443-2449.	1.4	291
254	A phase I/II dose escalation trial of EPO906 every 3 weeks in patients with non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2004, 22, 7248-7248.	0.8	0
255	ERCC1, RRM1 and XPD mRNA expression as a predictive marker of outcome in non-small-cell lung cancer (NSCLC) patients after platinum/gemcitabine induction chemotherapy followed by surgery. <i>Journal of Clinical Oncology</i> , 2004, 22, 7142-7142.	0.8	0
256	BRCA1 and HIF-1 α mRNA expression and chemoresistance in non-small-cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2004, 22, 7148-7148.	0.8	0
257	A phase I/II dose escalation trial of EPO906 every 3 weeks in patients with non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2004, 22, 7248-7248.	0.8	0
258	Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study. <i>Annals of Oncology</i> , 2003, 14, 1549-1554.	0.6	11
259	Preoperative High-Dose Cisplatin Versus Moderate-Dose Cisplatin Combined with Ifosfamide and Mitomycin in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Results of a Randomized Multicenter Trial. <i>Clinical Lung Cancer</i> , 2000, 1, 287-293.	1.1	12
260	Orbital Metastases from Transitional-Cell Cancer of the Urinary Bladder. <i>Urologia Internationalis</i> , 1991, 46, 82-84.	0.6	14